



**TTS PHARMA ANNOUNCES SIGNIFICANT MILESTONE WITH VALIDATION STATUS AWARDED FOR THEIR CANNABIDIOL (CBD) NOVEL FOOD DOSSIER RP521 BY THE FOOD STANDARDS AGENCY (FSA)**

**PRESS RELEASE**

TTS Pharma Limited (“TTS” or the “Company”), a leading UK supplier of high-quality, legal and safe cannabinoids including CBD for use in food and cosmetics, has announced that it is now confirmed as one of the few suppliers of botanical certified, organically-farmed hemp to have achieved full novel food validation by the UK’s Food Standards Agency (FSA).

The FSA mandated that all suppliers of CBD products must submit a novel food application by no later than 31 March 2021. This requirement has resulted in many brands being unable to sustain their operations. Despite the disruption in the CBD market, TTS Pharma embraced this decision as it signifies an elevation of industry standards. This move makes it more challenging for subpar operators to distribute potentially non-compliant and hazardous products in the market.

TTS Pharma has one of the most extensive UK CBD wellness product portfolios and diverse corporate Novel Food Regulatory package. TTS Pharma’s dossier covers over 860 finished CBD products, which range from tinctures and gummies, through to drinks, chewing gum and soft gel caps.

“Since the FSA called for CBD suppliers to comply with the Novel Food regulations, we have worked diligently to ensure that our customers, and the industry as a whole can have full confidence in both our in-house brand Endopure as well as our partners’ products, and today we are proud to announce that our pain-staking detailed approach to ensure the very highest quality & safety food standards has been fully recognised by the UK regulator,” said Robin Emerson, Director of Business Development & Media Affairs at TTS Pharma.

TTS Pharma welcomes the FSA imposing strict measures and controls to ensure consumer safety which both regulators and consumers across the UK (and Europe) are calling for increased visibility, traceability and improved quality of CBD based products.

“Today’s news is a significant milestone for TTS Pharma, our partners and consumers. We fully support measures that improve the overall safety and quality of CBD products in the UK and Europe, which in turn improves consumer confidence and trust in the products that we provide,” said Paul Atherton, Chairman of TTS Pharma.

**Notes to Editors & Press Enquiries:**

Paul Atherton, Chairman

[patherton@ttspharma.com](mailto:patherton@ttspharma.com)

Mobile +44 (0) 7768 402 132

Office +44 (0) 151 482 9160

Wilson Blaney, Quality Director

[wblaney@ttspharma.com](mailto:wblaney@ttspharma.com)

Mobile +44 (0) 7919 493 939

Office +44 (0) 151 482 9160

Robin Emerson, Director of Business Development & Media Affairs

[remerson@ttspharma.com](mailto:remerson@ttspharma.com)

Mobile +44 (0) 7555 606 007

Office +44 (0) 151 482 9160

**About TTS Pharma**

[www.ttspharma.com](http://www.ttspharma.com)

TTS Pharma is a private company, incorporated in England and Wales established in 2012, with offices in Liverpool. The Company holds deep industry expertise in extraction and separation of phytoactive ingredients and converting into finished product formats using sustained release formats. The Company supplies a growing number of CBD brands in UK, with exports to Germany, Portugal and South Africa. The Company sponsors a number of R&D projects at several leading UK Universities under Home Office Licenses and respects all existing legal and regulatory requirements in the UK. TTS Pharma is committed to a compliant and legal CBD supply chain and is one of the few companies to have this recognised by Trading Standards through its Primary Authority approval by Hertfordshire Trading Standards. TTS Pharma’s products follow a controlled, fully traceable process that complies with general Food Law (UK) including labelling and promotional materials for safe, repeatable use of CBD containing product.